Journal List > Diabetes Metab J > v.42(5) > 1142322

Yi: Letter: Cardio-Ankle Vascular Index as a Surrogate Marker of Early Atherosclerotic Cardiovascular Disease in Koreans with Type 2 Diabetes Mellitus (Diabetes Metab J 2018;42:285-95)
Early detection of subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2DM) is important, as atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in these patients [1]. Arterial stiffness is one of the earliest detectable manifestations of arterial dysfunction, and it is a strong predictor of future ASCVD events and all-cause mortality [2].
The cardio-ankle vascular index (CAVI) is a novel marker of arterial stiffness, which has been developed and widely studied in Japan [3]. It's non-invasive, easy to measure, unaffected by blood pressure, and superior in reproducibility compared with pulse wave velocity (PWV) [4]. Recent studies demonstrated the potential role of CAVI as a surrogate marker of atherosclerosis in patients with T2DM; CAVI may reflect endothelial function in T2DM [5], is useful for detecting coronary artery calcifications [67], and may be an important ASCVD risk factor in elderly (≥65 years) patients with T2DM [8].
In this article entitled “Cardio-ankle vascular index as a surrogate marker of early atherosclerotic cardiovascular disease in Koreans with type 2 diabetes mellitus,” Park et al. [9] investigated the correlation between surrogate markers of subclinical atherosclerosis including carotid artery intima medial thickness (IMT), ankle-brachial index (ABI), PWV, and CAVI and their optimal use in diabetic patients. They showed that a high CAVI was an independent risk factor in the non-ASCVD group for both 10-year ASCVD and atherosclerosis, concluding that CAVI is the most sensitive surrogate marker for identifying subclinical atherosclerosis in patients with T2DM without ASCVD. There are several issues that need to be addressed.
First, careful interpretation of CAVI results is required, because a high CAVI represents vascular stiffness as well as an increased vascular tone caused by smooth muscle contraction [4]. Furthermore, patients with a low ABI (<0.9) may show a falsely low CAVI and, therefore, are recommended to be excluded from CAVI study [234]; however, patients with a low ABI (<0.9) were not excluded in the present study. Second, a substantial number of patients in the non-ASCVD group might not have undergone examinations to detect ASCVD; therefore, asymptomatic ASCVD may have remained undetected. Third, Kim et al. [10] reported that a high CAVI in Korean patients with T2DM is associated with the presence of arterial plaque, increased IMT, and microvascular complications such as nephropathy and neuropathy. Microalbuminuria was the only marker of microvascular complications included in the present study, and showed no significant difference between ASCVD and non-ASCVD group. However, the possible reasons for this result were not discussed. Further investigations about the correlation between CAVI and microvascular complications are required. Finally, the authors divided the non-ASCVD group into three subgroups according to CAVI: low (CAVI <8), moderate (8≤CAVI<9), and high (CAVI ≥9). It would be helpful for readers to mention whether these criteria are from the manufacturer's instructions or some other references.


CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported.


1. Barnett KN, Ogston SA, McMurdo ME, Morris AD, Evans JM. A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with type 2 diabetes in Tayside, Scotland. Diabet Med. 2010; 27:1124–1129.
2. Saiki A, Sato Y, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawana H, Nagumo A, Nagayama D, Ohira M, Endo K, Tatsuno I. The role of a novel arterial stiffness parameter, cardio-ankle vascular index (CAVI), as a surrogate marker for cardiovascular diseases. J Atheroscler Thromb. 2016; 23:155–168.
3. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter: cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006; 13:101–107.
4. Sun CK. Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. Integr Blood Press Control. 2013; 6:27–38.
5. Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes. Int J Clin Pract. 2011; 65:1200–1201.
6. Chung SL, Yang CC, Chen CC, Hsu YC, Lei MH. Coronary artery calcium score compared with cardio-ankle vascular index in the prediction of cardiovascular events in asymptomatic patients with type 2 diabetes. J Atheroscler Thromb. 2015; 22:1255–1265.
7. Mineoka Y, Fukui M, Tanaka M, Tomiyasu K, Akabame S, Nakano K, Yamazaki M, Hasegawa G, Oda Y, Nakamura N. Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus. Heart Vessels. 2012; 27:160–165.
8. Hitsumoto T. Clinical significance of cardio-ankle vascular index as a cardiovascular risk factor in elderly patients with type 2 diabetes mellitus. J Clin Med Res. 2018; 10:330–336.
9. Park SY, Chin SO, Rhee SY, Oh S, Woo JT, Kim SW, Chon S. Cardio-ankle vascular index as a surrogate marker of early atherosclerotic cardiovascular disease in Koreans with type 2 diabetes mellitus. Diabetes Metab J. 2018; 42:285–295.
10. Kim KJ, Lee BW, Kim HM, Shin JY, Kang ES, Cha BS, Lee EJ, Lim SK, Lee HC. Associations between cardio-ankle vascular index and microvascular complications in type 2 diabetes mellitus patients. J Atheroscler Thromb. 2011; 18:328–336.

Dongwon Yi

Similar articles